阿托伐他汀对急性脑出血患者血脑屏障生物标志物的影响，一项试点临床试验

IF 1.3 Q4 CLINICAL NEUROLOGY Brain Hemorrhages Pub Date : 2023-06-01 DOI:10.1016/j.hest.2022.07.004

Leila Simani , Mahtab Ramezani , Nasrin Ahmadi , Fatima Abazari , Samira Raminfard , Maziyar Shojaei , Anahita Zoghi , Ehsan Karimialavijeh , Seyed Hossein Aghamiri , Hossein Pakdaman

{"title":"阿托伐他汀对急性脑出血患者血脑屏障生物标志物的影响，一项试点临床试验","authors":"Leila Simani , Mahtab Ramezani , Nasrin Ahmadi , Fatima Abazari , Samira Raminfard , Maziyar Shojaei , Anahita Zoghi , Ehsan Karimialavijeh , Seyed Hossein Aghamiri , Hossein Pakdaman","doi":"10.1016/j.hest.2022.07.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>Prior studies have shown statins provide neuroprotection by targeting secondary brain injury pathways and regulating cytokine production. We aimed to evaluate the association between statin administration and molecular outcomes in acute Intracranial hemorrhages (ICHs).</p></div><div><h3>Methods</h3><p>Adult patients with acute spontaneous ICH were recruited and randomly allocated into two groups: group A received atorvastatin (40 mg/day) orally in addition to routine antihypertensive medications, while group B only received routine antihypertensives. Serum levels of matrix metalloproteinase-9 (MMP-9), and vascular endothelial growth factor (VEGF), as primary outcomes, were measured at baseline, and after 45 days.</p></div><div><h3>Results</h3><p>Thirty-nine ICH patients (group A: 20; group B: 19) were analyzed. A notable elevation in VEGF and a reduction in MMP-9 levels were detected in group A compared to those in group B (P-value = 0.024 and 0.008, respectively).</p></div><div><h3>Conclusion</h3><p>Our data suggest that atorvastatin in the acute phase of ICH could improve the serum levels of neuroprotective molecular biomarkers.</p></div>","PeriodicalId":33969,"journal":{"name":"Brain Hemorrhages","volume":"4 2","pages":"Pages 53-56"},"PeriodicalIF":1.3000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The effect of atorvastatin on the blood-brain barrier biomarkers in acute intracerebral hemorrhage, a pilot clinical trial\",\"authors\":\"Leila Simani , Mahtab Ramezani , Nasrin Ahmadi , Fatima Abazari , Samira Raminfard , Maziyar Shojaei , Anahita Zoghi , Ehsan Karimialavijeh , Seyed Hossein Aghamiri , Hossein Pakdaman\",\"doi\":\"10.1016/j.hest.2022.07.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>Prior studies have shown statins provide neuroprotection by targeting secondary brain injury pathways and regulating cytokine production. We aimed to evaluate the association between statin administration and molecular outcomes in acute Intracranial hemorrhages (ICHs).</p></div><div><h3>Methods</h3><p>Adult patients with acute spontaneous ICH were recruited and randomly allocated into two groups: group A received atorvastatin (40 mg/day) orally in addition to routine antihypertensive medications, while group B only received routine antihypertensives. Serum levels of matrix metalloproteinase-9 (MMP-9), and vascular endothelial growth factor (VEGF), as primary outcomes, were measured at baseline, and after 45 days.</p></div><div><h3>Results</h3><p>Thirty-nine ICH patients (group A: 20; group B: 19) were analyzed. A notable elevation in VEGF and a reduction in MMP-9 levels were detected in group A compared to those in group B (P-value = 0.024 and 0.008, respectively).</p></div><div><h3>Conclusion</h3><p>Our data suggest that atorvastatin in the acute phase of ICH could improve the serum levels of neuroprotective molecular biomarkers.</p></div>\",\"PeriodicalId\":33969,\"journal\":{\"name\":\"Brain Hemorrhages\",\"volume\":\"4 2\",\"pages\":\"Pages 53-56\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Brain Hemorrhages\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2589238X2200047X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain Hemorrhages","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2589238X2200047X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的先前的研究表明，他汀类药物通过靶向继发性脑损伤途径和调节细胞因子的产生来提供神经保护。我们旨在评估他汀类药物给药与急性颅内出血（ICHs）分子结果之间的关系。方法招募成年自发性ICH患者，并将其随机分为两组：A组除常规降压药物外，还口服阿托伐他汀（40mg/天），而B组仅接受常规降压药物。在基线和45天后测量血清基质金属蛋白酶-9（MMP-9）和血管内皮生长因子（VEGF）水平，作为主要结果。结果分析了39例脑出血患者（A组：20例；B组：19例）。与B组相比，A组VEGF显著升高，MMP-9水平显著降低（P值分别为0.024和0.008）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

The effect of atorvastatin on the blood-brain barrier biomarkers in acute intracerebral hemorrhage, a pilot clinical trial

Objective

Prior studies have shown statins provide neuroprotection by targeting secondary brain injury pathways and regulating cytokine production. We aimed to evaluate the association between statin administration and molecular outcomes in acute Intracranial hemorrhages (ICHs).

Methods

Adult patients with acute spontaneous ICH were recruited and randomly allocated into two groups: group A received atorvastatin (40 mg/day) orally in addition to routine antihypertensive medications, while group B only received routine antihypertensives. Serum levels of matrix metalloproteinase-9 (MMP-9), and vascular endothelial growth factor (VEGF), as primary outcomes, were measured at baseline, and after 45 days.

Results

Thirty-nine ICH patients (group A: 20; group B: 19) were analyzed. A notable elevation in VEGF and a reduction in MMP-9 levels were detected in group A compared to those in group B (P-value = 0.024 and 0.008, respectively).